Entrada Therapeutics (TRDA) to Announce Quarterly Earnings on Wednesday

Entrada Therapeutics (NASDAQ:TRDA) is anticipated to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Entrada Therapeutics to announce earnings of ($1.0493) per share and revenue of $2.2340 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.11. The firm had revenue of $0.88 million during the quarter, compared to analysts’ expectations of $2.92 million. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. On average, analysts expect Entrada Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Entrada Therapeutics Price Performance

Shares of TRDA opened at $5.83 on Wednesday. The firm has a 50-day moving average of $6.80 and a 200-day moving average of $9.91. Entrada Therapeutics has a one year low of $4.93 and a one year high of $16.45. The company has a market cap of $226.32 million, a PE ratio of -1.46 and a beta of -0.26.

Insider Activity at Entrada Therapeutics

In related news, insider Natarajan Sethuraman sold 25,907 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $15.39, for a total value of $398,708.73. Following the transaction, the insider owned 216,317 shares in the company, valued at approximately $3,329,118.63. This represents a 10.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernhardt G. Zeiher purchased 5,000 shares of the stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $5.86 per share, for a total transaction of $29,300.00. Following the completion of the acquisition, the director owned 5,000 shares in the company, valued at approximately $29,300. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 9.49% of the stock is owned by company insiders.

Institutional Trading of Entrada Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after purchasing an additional 42,479 shares during the period. Rhumbline Advisers increased its position in Entrada Therapeutics by 8.3% during the second quarter. Rhumbline Advisers now owns 39,095 shares of the company’s stock worth $263,000 after acquiring an additional 2,982 shares during the period. American Century Companies Inc. raised its stake in Entrada Therapeutics by 10.8% in the 2nd quarter. American Century Companies Inc. now owns 75,094 shares of the company’s stock worth $505,000 after purchasing an additional 7,301 shares in the last quarter. Prudential Financial Inc. raised its stake in Entrada Therapeutics by 23.4% in the 2nd quarter. Prudential Financial Inc. now owns 28,340 shares of the company’s stock worth $190,000 after purchasing an additional 5,370 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Entrada Therapeutics by 34.2% in the 2nd quarter. Invesco Ltd. now owns 22,393 shares of the company’s stock valued at $150,000 after purchasing an additional 5,702 shares during the period. 86.39% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald began coverage on shares of Entrada Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating for the company. Roth Capital set a $10.00 price target on Entrada Therapeutics in a research report on Friday, May 8th. Weiss Ratings lowered Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. HC Wainwright cut Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Finally, Guggenheim reduced their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, June 8th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $17.50.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.